BACKGROUND It is unclear whether the routine follow up (FU) coronary angiography (CAG) regardless of patient's symptoms after successful primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) in acute ST elevation myocardial infarction (STEMI) patients (pts) is beneficial or not.
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METHODS The study population consisted of 447 consecutive STEMI patients (pts) underwent PCI with unrestricted utilization of DESs from January 2004 to May 2011. Routine FU CAG was performed between 6 to 9 months following index PCI and was decided by individual physician's discretion. Rests of the pts were clinically followed and ischemic driven events were captured. Clinical events including mortality, myocardial infarction (MI) and clinically driven PCI before 9 months were excluded in both groups. Cumulative clinical outcomes up to 3 years were compared between the Routine CAG group (n ¼ 244 pts) and Clinical FU group (n ¼ 203 pts). To adjust potential confounders, a propensity score matched (PSM) analysis was performed using the logistic regression model. RESULTS After PSM analysis, 2 propensity-matched groups (129 pairs, n ¼ 258 pts, C-statistic ¼ 0.762) were generated and the baseline characteristics of the two groups were balanced. At 3 years, the incidence of individual hard endpoints including mortality, MI, major adverse cardiac events (MACEs) were similar between the two groups excepted that Routine CAG group had higher incidence of any revascularization, particularly non-target vessel revascularization (NTVR) than the control group (Table) .
CONCLUSION Despite the expected beneficial effects, routine FU CAG following index primary PCI with DESs in STEMI pts was associated with higher incidence of repeat PCI including NTVR up to 3-year clinical follow-up. BACKGROUND We compared the efficacy and safety of sirolimuseluting stents with Parylene C (SESs), everolimus-eluting stents with poly n-butyl methacrylate (EESs), biodegradable stent (BP-DESs), and endothelial progenitor cell capture stents (EPCCSs).
METHODS From the IRIS-DES registry, we identified 1517 patients treated using PCI with SESs (N ¼ 372), EESs (N ¼ 405), BP-DESs (N ¼ 300), and EPCCSs (N ¼ 440) in ST-elevation myocardial infarction (STEMI). Major adverse cardiac events (MACE) were defined using composite of death, myocardial infarction, and target vessel revascularization at 24 months.
RESULTS The average number of stent used was 1.6 AE 0.8. At 2 years, there was no difference in the incidence of MACE (8.5% in SESs, 9.9% in EES, 10.2% in BP-DES, and 12.8% in EPCCS, P ¼ 0.281), death (5.0% in SESs, 4.3% in EES, 4.4%in BP-DES, and 6.2% in EPCCS, P ¼ 0.718), MI (0.6% in SESs, 1.6% in EES, 1.5%in BP-DES, and 1.5% in EPCCS, P ¼ 0.572), and TVR (3.8% in SESs, 5.9% in EES, 4.8% in BP-DES, and 6.5% in EPCCS, P ¼ 0.313). The EPCCSs group showed trend of higher rate in any revascularization, but no significantly statistical difference (6.6% in SESs, 9.1% in EES, 7.2% in BP-DES, and 11.6% in EPCCS, P ¼ 0.313). The cumulative rates of Academic Research Consortium defined definite stent thrombosis were 0.3% in SESs, 1.2% in EESs, 0.7% in BPDESs, and 1.6% in EPCCSs (P ¼ 0.239).
CONCLUSION The 4 different DESs showed no significant difference in clinical outcome at 2-year follow-up in patients with STEMI. 
